August 25, 2020 Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions C-Path’s Crohn's Disease Biomarkers Pre-Consortium funded by The Helmsley Charitable Trust is proud to announce its...
August 21, 2020 C-Path’s PKDOC and The PKD Foundation Set to Collaborate Once Again Polycystic Kidney Disease (PKD) is an inherited disorder in which clusters of cysts develop in the kidneys. There are more than 20
August 16, 2020 Remote Digital Monitoring for Medical Product Development Izmailova ES, Wagner JA, Ammour N, Amondikar N, Bell‐Vlasov A, Berman S, Bloomfield D, Brady LS, Cai X, Calle RA, Campbell M...
August 14, 2020 Demystifying Submissions of eCOA Documentation for Ethics Review: Are We Making Submissions More Difficult than Necessary?
August 14, 2020 ePRO Consortium Announces Publication of Open Access Article C-Path’s ePRO Consortium is pleased to announce that “Demystifying Submissions of eCOA Documentation for Ethics
August 11, 2020 Necrotizing Enterocolitis: Using Regulatory Science and Drug Development to Improve Outcomes , September 2019
July 30, 2020 C-Path Partners with CHDR to Expand Global Collaborations The Critical Path Institute and the Centre for Human Drug Research (CHDR) have joined forces to expand global collaborations for b
July 22, 2020 C-Path’s PSTC, D-RSC Receive Positive FDA Response for Drug-Induced Skeletal Muscle Injury Biomarkers Safety biomarkers aim to provide an additional tool for detecting acute drug-induced skeletal muscle injury in phase 1 clinical tr